Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in R/R B-ALL
NCT05961696Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mosunetuzumab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Jul 2023; status: withdrawn.
02
Drugs
mosunetuzumab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05961696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961696.